Skip to content
RDL Network logo
Linvoseltamab (LINVO) + Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Initial Results from the LINKER-MM2 Trial — Morten Salomo (2025) | RDL Network